IMV Key Statistics, Chart & Performance
The current stock price of IMV is 0.8225 USD. In the past month the price increased by 52.46%. In the past year, price decreased by -93.09%.
IMV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About IMV
Company Profile
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
Company Info
IMV INC
130 Eileen Stubbs Ave Suite 19
Dartmouth NOVA SCOTIA B3B 2C4 CA
CEO: Frederic Ors
Employees: 63
Phone: 19024921819.0
IMV INC / IMV FAQ
What does IMV INC do?
IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 63 full-time employees. The company went IPO on 2007-10-24. The firm is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other candidates include DPX-RSV and DPX-COVID-19. DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is focused on developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.
What is the stock price of IMV INC today?
The current stock price of IMV is 0.8225 USD. The price decreased by -2.55% in the last trading session.
Does IMV INC pay dividends?
IMV does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMV stock?
IMV has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is IMV INC (IMV) expected to grow?
The Revenue of IMV INC (IMV) is expected to decline by -80.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is IMV INC worth?
IMV INC (IMV) has a market capitalization of 9.63M USD. This makes IMV a Nano Cap stock.
Can you provide the ownership details for IMV stock?
You can find the ownership structure of IMV INC (IMV) on the Ownership tab.
IMV Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMV. When comparing the yearly performance of all stocks, IMV is a bad performer in the overall market: 98.15% of all stocks are doing better.
IMV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMV. IMV may be in some trouble as it scores bad on both profitability and health.
IMV Financial Highlights
Over the last trailing twelve months IMV reported a non-GAAP Earnings per Share(EPS) of -4.59. The EPS increased by 4.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMV Forecast & Estimates
7 analysts have analysed IMV and the average price target is 21.8 USD. This implies a price increase of 2550.76% is expected in the next year compared to the current price of 0.8225.
For the next year, analysts expect an EPS growth of 20.34% and a revenue growth -80.66% for IMV